Related Concept Videos
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Cost-effectiveness of pre-emptive pharmacogenetic testing: An umbrella review.
PloS one·2026
Same author
Preference-based scoring algorithm to estimate societal utilities based on the patient-reported experience of cognitive impairment in schizophrenia (PRECIS) instrument.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author
Legal implications of joint clinical assessments under the EU HTA regulation.
Health economics, policy, and law·2026
Related Experiment Video
Updated: May 26, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
Martine Hoogendoorn1, Maureen P M H Rutten-van Mölken, Rudolf T Hoogenveen
1Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands. hoogendoorn@bmg.eur.nl
Summary
A new stochastic population model for chronic obstructive pulmonary disease (COPD) evaluates interventions. The model assesses quality-adjusted life years, costs, and mortality, aiding policy decisions for COPD management.
Area of Science:
- Pulmonary Medicine
- Health Economics
- Biostatistics
Background:
- Chronic obstructive pulmonary disease (COPD) management requires robust models to predict disease progression and intervention effectiveness.
- Understanding the long-term impact of COPD exacerbations on quality of life, healthcare costs, and mortality is crucial for effective treatment strategies.
Purpose of the Study:
- To develop a stochastic population model for chronic obstructive pulmonary disease (COPD) that simulates disease progression.
- To incorporate the effects of COPD exacerbations on health-related quality of life, healthcare costs, disease progression, and mortality.
- To enable assessment of a wide range of interventions for COPD management.
Main Methods:
- A multistate Markov model with time-varying transition rates was developed, incorporating age, sex, smoking status, COPD severity, and exacerbation type.
- The model simulates annual changes in COPD prevalence, disease progression (decline in FEV1), and mortality.
- Quality-adjusted life years, total exacerbations, and COPD-related healthcare costs were primary outcome variables, with parameters derived from meta-analysis and expressed as probability distributions.
Main Results:
- Pharmacologic intervention (€8,300/QALY), smoking cessation (€10,800/QALY), and combination therapy (€8,700/QALY) demonstrated cost-effectiveness compared to minimal treatment.
- Pulmonary rehabilitation showed a higher cost/QALY of €17,200.
- Interventions had a 58%-100% probability of being cost-effective at a €20,000 ceiling ratio.
Conclusions:
- The developed COPD model offers policymakers insights into the long-term costs and effects of interventions across the continuum of care.
- The model accounts for uncertainty in outcomes, providing a comprehensive tool for evaluating strategies from primary prevention to severe COPD management.